Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
16
|
pubmed:dateCreated |
1998-8-17
|
pubmed:abstractText |
microolecular design can overcome the metabolic instability of Delta7-PGA1, while maintaining its antitumor potency. Saturation of the C(13)-C(14) double bond enhances the biological stability but decreases the antiproliferative activity. Configurational inversion of the isomerase-sensitive C(12) stereocenter from the natural S to the unnatural R geometry not only enhances biological stability but also significantly suppresses the growth of the tumor cells. The 12R derivatives markedly increase the induction of p21, a Cdk inhibitor, leading to sharp cell cycle arrest at the G1 phase at a dose level so low that at this dose Delta7-PGA1 methyl ester scarcely exerts an effect. These conspicuous biological properties lead to long-term suppression of tumor cell growth. The structure-stability relationship demonstrates that the stability of prostaglandins (PGs) is crucially controlled by the C(12) configuration and is unaffected by the geometry of the hydroxy-bearing C(15). The successful design of antitumor PGs resistant to enzymatic metabolism provides a new strategy applicable to creating a useful PG for cancer chemotherapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cdkn1a protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclins,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0022-2623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
30
|
pubmed:volume |
41
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3084-90
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9685248-Animals,
pubmed-meshheading:9685248-Antineoplastic Agents,
pubmed-meshheading:9685248-Cell Division,
pubmed-meshheading:9685248-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:9685248-Cyclins,
pubmed-meshheading:9685248-Drug Design,
pubmed-meshheading:9685248-Drug Screening Assays, Antitumor,
pubmed-meshheading:9685248-Drug Stability,
pubmed-meshheading:9685248-G1 Phase,
pubmed-meshheading:9685248-Humans,
pubmed-meshheading:9685248-Prostaglandins,
pubmed-meshheading:9685248-Rats,
pubmed-meshheading:9685248-Stereoisomerism,
pubmed-meshheading:9685248-Structure-Activity Relationship,
pubmed-meshheading:9685248-Tumor Cells, Cultured
|
pubmed:year |
1998
|
pubmed:articleTitle |
Rational design of antitumor prostaglandins with high biological stability.
|
pubmed:affiliation |
Department of Biomolecular Science, Faculty of Engineering, Gifu University, Yanagido 1-1, Gifu 501-1193, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|